Discover
XTLB
XTL Biopharmaceuticals Ltd.
2.92
4 x 2.61
30 x 2.86
bid
ask
+
0.03
1.04%
4 @ 04:00 PM
2.83 -0.09 (3.08%)
| Ytd | 25.86% | |
| 1y | -59.89% |
2.75
day range
2.92
0.53
52 week range
4.87
| Open | 2.75 | Prev Close | 2.89 | Low | 2.75 | High | 2.92 | Mkt Cap | 6.91M |
| Vol | 4.30K | Avg Vol | 1.98M | EPS | N/A | P/E | N/A | Forward P/E | N/A |
| Beta | 1.45 | Short Ratio | 3.35 | Inst. Own | 1.92% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 2.59 | 200-d Avg | 3.24 | 1yr Est | 0.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-12-25 | 2024-09 | 0 | N/A | N/A | N/A |
| 2024-10-03 | 2024-06 | 0 | N/A | N/A | N/A |
| 2024-05-13 | 2024-03 | 0 | 0.1 | N/A | N/A |
| 2024-04-03 | 2023-12 | 0 | N/A | N/A | N/A |
| 2023-11-15 | 2023-09 | 0 | -0.04 | N/A | N/A |
| 2023-08-10 | 2023-06 | 0 | -0.07 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2015-05-08 | HC Wainwright & Co. | Upgrade | Buy |
Profile
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Noked Israel Ltd. | 198.89K | 350.04K | 3.65% |
| 2024-09-29 | Morgan Stanley | 26.45K | 46.55K | 0.49% |
| 2024-09-29 | Rhumbline Advisers | 6.52K | 11.47K | 0.12% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 8.90K | 15.67K | 0.16% |
Split
| Split | Date |
|---|---|
| 1 : 4 | 2026-03-25 |
| 1 : 5 | 2017-02-10 |
| 0.1 : 1 | 2012-10-04 |
| 0.2 : 1 | 2009-06-22 |